INTRODUCTION
Prostate cancer (PCa) is the second most frequent malignancy in men worldwide, accounting for more than 300 000 cancer-related deaths per year. In China, approximately 6.03% of adult males were suspected to have PCa in 2015, and the annual incidence of PCa in the Chinese population is increasing by 4.7%. 1 Actionable molecular sequencing is a plausible and promising strategy for improving treatment results by targeted therapy. However, the incidence, prognosis, and treatment outcomes differ among ethnicities due to heterogeneity at the genetic and phenotypic levels. 2, 3 Genetic and transcriptional alterations have been studied extensively in Western populations; however, little is known about the genomic aberrations associated with the pathogenesis of PCa in Chinese populations.
Next-generation sequencing (NGS) has enabled extensive profiling of genome-wide alterations during PCa tumorigenesis. Recent sequencing studies have revealed various somatically acquired genetic, epigenetic, and transcriptional changes in PCa, such as alterations in phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), tumor protein P53 (TP53), speckle type BTB/POZ protein (SPOP), chromodomain helicase DNA-binding protein 1 (CHD1), and external transcribed spacer (ETS) transcription factor family. 4 Notably, NGS approaches not only provide numerous insights into the ORIGINAL ARTICLE Integrative molecular characterization of Chinese prostate cancer specimens
RESULTS

Application of integrative genetic/transcriptomic assays for Chinese clinical formalin-fixed paraffin-embedded (FFPE) PCa samples
To identify the genetic and transcriptomic spectra of genes associated with the pathogenesis of PCa in Chinese patients, we performed integrative DNA-and RNA-based assays requiring only approximately 50 ng of FFPE DNA and 500 ng of FFPE RNA. The assays consist of a multiplex PCR-based panel for gene sequencing and a qRT-PCR array for the detection of gene expression. The gene sequencing panel was used for target enrichment of the exonic regions of the 32 most commonly mutated genes in human PCa samples, and the amplification or deletion of these genes was evaluated as described previously. 9 The qRT-PCR assay included 28 genes, including robust housekeeping genes, AR transcriptional modules, cell cycle-related genes, and genes defining molecular subtypes or molecular drivers based on previous transcriptomic studies (Supplementary Table 1 ). The integrative assays were performed using samples obtained from a cohort of 46 Chinese patients with PCa after radical prostatectomy or transurethral resection of the prostate ( Supplementary Table 2 ).
Mutation and copy number variant detection by targeted gene sequencing
Ion Torrent NGS after multiplex PCR-based targeted enrichment was applied to 46 FFPE PCa samples, yielding an average of 6 243 762 mapped reads and an average coverage of 3527× (1156-5419×) over targeted bases per sample. The complete coverage details are provided in Supplementary Table 3 . An initial 5909 variants were filtered for quality, SNPs, and functional relevance. As described previously, 8 we identified 245 nonsynonymous (missense, in-frame deletion, nonsense, stop-loss, and frameshift) mutations with an allele frequency of ≥3% in all sequencing specimens (average: 5; range: 1-34) across 27 genes. All high-confidence mutations are shown in a heatmap in Figure 1 and are detailed in Supplementary Table 4 . The most frequently mutated genes were lysine (K)-specific methyltransferase 2D (KMT2D, 63.04%), zinc finger homeobox 3 (ZFHX3, 50.00%), A-kinase anchoring protein 9 (AKAP9, 32.61%), GLI family zinc finger 1 (GLI1, 32.61%), thrombospondin type 1 domain containing 7B (THSD7B, 19 .57%), APC regulator of WNT signaling pathway (APC, 15.22%), cyclin-dependent kinase 12 (CDK12, 15.22%), lysine demethylase 4B (KDM4B, 15.22%), mediator complex subunit 12 (MED12, 15.22%), and zinc finger protein 595 (ZNF595, 15.22%).
Using an approach adapted from multiplexed PCR-based targeted Ion Torrent NGS data, 9 we simultaneously assessed CNVs in 25 genes, yielding a total of 312 high-level CNVs across the 46 PCa specimens (average: 7 high-level CNVs per sample; range: 0-15). A copy number heatmap for all samples is shown in Figure 1 .
Assessment of critical PCa transcriptomic alterations by qRT-PCR
We performed qRT-PCR using RNA isolated from the sequencing cohort of 43 FFPE PCa samples (the sequencing samples, excluding those with low RNA quality). Normalized target gene expression is shown in Figure 2 . Combined with target sequencing, we performed basic PCa molecular subtyping for the 43 Chinese patients (Figure 1 and 2) . TMPRSS2:ERG was detected in nine cancer samples, which showed approximately 70-fold greater TMPRSS2:ERG expression than the median of the 34 other TMPRSS2:ERG-negative samples. Two samples showed marked ETS variant 4 (ETV4) overexpression, indicating the presence of a gene fusion in this ETS family member. Overexpression of serine peptidase inhibitor, Kazal type 1 (SPINK1), was identified in four samples (the SPINK1 + subtype). Moreover, by targeted gene sequencing, we observed high-confidence SPOP mutations in samples PR110, PR112, and PR203, each of which was ETS-negative by qRT-PCR. Among these samples, PR203 also showed high SPINK1 expression, suggesting the overlap of these alterations.
AR-targeted genes were included based on previous microarray analyses of genes regulated by androgens in PCa. 10 Our results showed that the AR signature was heterogeneous in all treatment-naïve PCa specimens. AR activity might predict the response to therapies targeting the AR axis. PR315 and PRY04 had markedly lower AR activity than that of other samples, suggesting different responses to anti-androgen therapy compared with those of samples with high AR activity.
In addition, four cell cycle-related genes, nucleolar and spindleassociated protein 1 (NUSAP1), kinesin family member 11 (KIF11), cell division cycle 20 (CDC20), and forkhead box M1 (FOXM1), were evaluated as indicators of cell proliferation, a fundamental aspect of tumor biology. 11 Most of the samples showed relatively low expression of cell cycle progression genes, suggesting low aggressiveness in the metastasis (P = 0.0012), NCCN risk stratification (P = 0.0011), and EAU risk classification (P = 0.00039) (Supplementary Figure 1) . These results indicated a high predictive value of these risk factors, which may contribute to clinical decision-making in Chinese patients with PCa.
KMT2D is positively correlated with the AR signaling pathway in PCa
Another advantage of the integrative genetic/transcriptomic assay is the ability to explore the correlations underlying recurrently altered genes. We performed a correlation analysis of the expression of the 27 robust target genes across all samples. We observed correlated expression of genes within the AR signaling pathway and cell cycle progression modules (Figure 4a) . In particular, positive correlations were identified between KMT2D and AR (r = 0.31, P = 0.046), the AR downstream target calcium/calmodulin-dependent protein kinase kinase 2 (CAMKK2) (r = 0.45, P = 0.046), the cell cycle progression gene CDC20 (r = 0.32, P = 0.037), and SPINK1 (r = 0.40, P = 0.008) (Figure 4b) . Because the AR signaling pathway is indispensable for PCa carcinogenesis, we further validated the correlation between KMT2D and AR signaling using the Cancer Genome Atlas Prostate Adenocarcinoma (TCGA-PRAD) data. Consistent with our qRT-PCR results, KMT2D expression was strongly correlated with AR mRNA levels (r = 0.70, P < 0.001; Figure 4c left) and AR protein levels (r = 0.32, P < 0.001; Figure 4c right). Patients with AR-V7 had higher KMT2D expression (P = 0.036; Figure 4d ), suggesting that KMT2D contributes to the AR splice variants. These findings highlight the close linkage between KMT2D and AR signaling and suggest that KMT2D plays a critical role in the activation of the AR axis in PCa.
DISCUSSION
We used a rapid, robust, and high-throughput approach for the characterization of gene mutations, copy number variants, and crucial transcriptomic events in Chinese patients with PCa by combined multiple-PCR-based deep NGS and qRT-PCR. This integrative assay required only 50 ng of DNA and 500 ng of RNA, which can be co-isolated from most routine clinical samples, making it practical for academic research settings as well as routine clinical settings. In this study, we added to the current knowledge of the genetic heterogeneity of prostate tumors among ethnic populations and identified correlations between clinical and prognostic factors and recurrently altered genes, providing a basis for therapeutic decisions. Moreover, we observed a close relationship between KMT2D and AR signaling in a gene co-expression analysis, highlighting the important role of KMT2D in the activation of the AR axis in PCa.
Our findings expand our understanding of the ethnicity-specific molecular landscape of PCa. As a heterogeneous disease, previous studies have reported notable disparities in PCa epidemiology among ethnic groups. 13 Emerging evidence suggests that these differences might be the result of distinct molecular characteristics. 14, 15 Ren kinase; however, Wu et al. 36 found that inactivation of CDK12 could define a distinct subtype of PCa, leading to increased neoantigen burden and T cell infiltration. Moreover, the loss of CDK12 is associated with genomic instability and predicts a worse poor prognosis in breast cancer. 37 These findings further indicated that these genomic events are associated with clinical parameters and might serve as biomarkers in Chinese patients. However, given the small sample size, an independent cohort of patients is needed to confirm these results in the future.
Our integrative genetic/transcriptomic assays might also have utility for personalized medicine. The five main pathways involved in our analysis have clinical implications, and drugs targeting these alterations have been developed. 12 For instance, the PI3K/AKT/PTEN pathway was upregulated in 34.78% of samples in our cohort. Therapeutically, to target this pathway, pan-PI3K and dual PI3K-mTOR inhibitors have been developed, and the AKT-targeting drugs BKM120 and MK-2206 show clinical efficacy in PCa. 6 Cancer immunotherapies have become a revolutionized approach to the treatment of cancers, including PCa. 38 The inactivation of CDK12 delineates a distinct immunogenic class of PCa, and a clinical study showed that patients with metastatic PCa who harbor a biallelic CDK12 loss have a higher likelihood of response to immunotherapy. 36 In our cohort, 15.22% (7/46) of patients had CDK12 mutations. Among them, PR110, PR113, PR206, and PR309 were in an advanced state and relapsed after radical prostatectomy. These patients might benefit from immune checkpoint inhibitors after progression to the final stage of this disease. In addition, we evaluated AR signaling pathway activity. Consistent with previous results, most of our treatment-naïve cases showed high AR activity, indicating a better response to anti-androgen therapy. 10 Compared with other cases, PR305 and PRY04 showed decreased AR activity, suggesting a heterogeneous response. Therefore, careful attention is needed when administering hormonal therapy. Above all, our findings suggest that molecular profiling using a targeted panel could provide valuable information, i.e., personalized mutation profiles for actionable targets, thereby contributing to clinical treatment decisions.
Notably, we detected a close link between KMT2D and the AR signaling pathway in our cohort using the integrative assays. These results were further confirmed using an additional dataset, TCGA-PRAD, showing that KMT2D expression was positively correlated with AR expression at the mRNA and protein level. Moreover, AR-V7-positive patients had high KMT2D expression levels. KMT2D is a histone lysine methyltransferase involved in the monomethylation of H3K4 residues (histone H3 lysine 4-monomethylation, H3K4me1). We previously concluded that, in PCa, KMT2D epigenetically upregulates LIF receptor alpha (LIFR) and Kruppel-like factor 4 (KLF4) expression, activating PI3K/AKT and epithelial-mesenchymal transition (EMT) oncogenic pathways and promoting PCa outgrowth and metastasis. 8 Recent studies have reported that KMT2D is a transcriptional coactivator that recognizes target genes via DNA-bound transcription factors. 39 In breast cancer, KMT2D is required for FOXA1, PBX homeobox 1 (PBX1), and estrogen receptor (ER) recruitment and activation and contributes to resistance to PI3Kα inhibitors. 40 Thus, the positive correlation between KMT2D and the AR signaling pathway raises the possibility that KMT2D serves as a transcriptional coactivator and controls AR activation through posttranslational modification of epigenetic regulators. Further research is required to comprehensively clarify the role of KMT2D in PCa.
CONCLUSION
We applied an integrative approach to identify the critical genomic and transcriptomic events in 46 routine clinical Chinese PCa samples. et al. 16 identified salient genetic characteristics of PCa in Chinese patients. Similarly, the molecular profiles of Chinese patients with PCa identified in our cohort differed from that of Western patients. The most frequently mutated genes were KMT2D, ZFHX3, AKAP9, and GLI1 in our cohort; recurrently mutated genes in Western populations are SPOP, titin (TTN), TP53, mucin 16 (MUC16), MED12, and Forkhead Box A1 (FOXA1). 17 These results might be due to either de novo ethnicity-specific mutations in Chinese patients or high-depth sequencing effects. Asian and Western populations have distinct genetic polymorphisms, 18, 19 familial aggregation, 20 and diet. 21 Basic science and epidemiological studies have demonstrated that these factors have a role in the clinical heterogeneity of PCa. 22 Thus, the differences in these factors might influence the tumor genome and contribute to the ethnic genetic heterogeneity of PCa. Moreover, unlike other large-scale sequencing studies in Western patients, in which the sequencing depth is about 100×, in this study, we focused on 32 PCa-correlated genes and the average sequencing depth was approximately 3527×. The higher sequencing depth can remarkably increase the sensitivity of single-nucleotide variant detection; 23 hence, the high coverage might account for the high mutation frequency of some genes in our cohort.
In addition to mutation, using an algorithm developed by Grasso et al., 9 we detected CNVs in our amplicon-based sequencing data. We observed copy number gains of KMT2D, AKAP9, MYC, and GLI and copy number losses of PTEN, RB1, and APC in Chinese patients. PTEN inactivation and copy number deletions account for the majority of PTEN loss-of-function cases. 5 We found a low frequency of these genomic changes, i.e., 23.9% (11/46) in our cohort, compared with approximately 40% in Western samples. 15 MYC amplification and RB1 deletion are two major CNVs detected in multiple genomic analyses. 12 We also found MYC gains (60.9%, 28/46) and RB1 deletions (45.7%, 21/46) in our samples. However, the frequencies were higher than those in Western populations, in which MYC amplification and RB1 were deleted in 7.4% (37/498) and 16.3% (81/498) cases from TCGA-PRAD, respectively. For critical transcriptomic events, we identified a lower frequency of the ETS fusion (23.9%, 11/46) in our patients than in Caucasian patients (with a prevalence of approximately 50%). 24 The results of other large-scale studies further support the low frequency of the ETS fusion in Asian patients, 14,15,25 indicating regional differences in molecular subtypes.
Furthermore, we identified clinical associations for the recurrently altered genes. Copy number deletion of RB1 was remarkably correlated with a high risk of disease progression. ETS fusion and GLI1 mutations were more common in patients with a higher T stage and distant metastasis, respectively, than in other patients. Importantly, poor prognosis was associated with various alterations, including MYC amplification, RB1 deletion, APC mutation or deletion, and CDK12 mutation. MYC and RB1 are involved in the regulation of the cell cycle; amplification of MYC prompts progression from G1 to S phase, 17, 26 and MYC amplification status is predictive of biochemical recurrence after prostatectomy. 27 However, its mRNA or protein levels show weak prognostic ability. 28 RB1 is a critical negative regulator of the G1-S checkpoint and is responsible for repressing E2F family transcription factors. 29 According to a recent study, RB1 deletion occurs early in PCa, prior to subclonal diversification. 30 Consistent with our results, a large PCa tissue microarray study indicated that the deletion of RB1 is linked to an adverse phenotype and poor prognosis in this disease. 31 APC is a multifunctional protein and is as a negative regulator of the Wnt pathway. 32 The inactivation of APC by mutations or hypermethylation is associated with tumor aggressiveness. 33, 34 In Chinese populations, Geng et al. 35 showed that APC mutations are associated with both PCa progression and all-cause mortality. CKD12 is a cyclin-dependent This approach is helpful in characterizing retrospective material and analyzing correlations between clinical parameters and molecular changes. More importantly, focused assessments of genomic and transcriptomic features are important for disease pathology research as well as for advancements in personalized medicine.
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